{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:06:21Z","timestamp":1775091981392,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ejca.2008.01.016","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T23:56:25Z","timestamp":1204847785000},"page":"674-682","source":"Crossref","is-referenced-by-count":7,"title":["Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies"],"prefix":"10.1016","volume":"44","author":[{"given":"Sandrine","family":"Faivre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Delbaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Namouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2008.01.016_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/anie.199615671","article-title":"Epothilone A and B \u2013 Novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution","volume":"35","author":"H\u00f6fle","year":"1996","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ejca.2008.01.016_bib2","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a TAXOL-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2008.01.016_bib3","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1074\/jbc.272.4.2534","article-title":"Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin in cells resistant to paclitaxel (TAXOL\u00ae)","volume":"272","author":"Kowalski","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2008.01.016_bib4","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.01.016_bib5","unstructured":"Bristol Myers Squibb. BMS-247550, Investigator\u2019s Brochure. Wallingford, CT: Bristol Myers Squibb, 2001."},{"key":"10.1016\/j.ejca.2008.01.016_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","article-title":"Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors","volume":"10","author":"Mani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.01.016_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.20977","article-title":"A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days","volume":"103","author":"Zhuang","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2008.01.016_bib8","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib9","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.2003.03.063","article-title":"Phase I and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intraveinously on a daily schedule for five days","volume":"21","author":"Abraham","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0305-7372(94)90011-6","article-title":"Topoisomerase I inhibitors: Topotecan and irinotecan","volume":"20","author":"Creemers","year":"1994","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2008.01.016_bib11","first-page":"663","article-title":"Clinical trials with the topoisomerase I inhibitors","volume":"19","author":"Burris","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib12","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.bjc.6601456","article-title":"Progress in treatment of small-cell lung cancer: role of CPT-11","volume":"89","author":"Saijo","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2008.01.016_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.01.016_bib15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2008.01.016_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2008.01.016_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-4347(92)80156-K","article-title":"Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients","volume":"575","author":"Barilero","year":"1992","journal-title":"J Chromatogr"},{"key":"10.1016\/j.ejca.2008.01.016_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1023\/A:1013157727506","article-title":"Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks","volume":"12","author":"Rothenberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","article-title":"Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate at constant rate","volume":"82","author":"Caussanel","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2008.01.016_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdf219","article-title":"Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma","volume":"13","author":"Faivre","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib21","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1200\/JCO.2005.09.357","article-title":"Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies","volume":"23","author":"Faivre","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib22","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.1200\/JCO.2005.08.004","article-title":"Fishing for new drugs","volume":"23","author":"Calvert","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib23","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1158\/1078-0432.CCR-04-0869","article-title":"Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials","volume":"10","author":"Raymond","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2008.01.016_bib24","article-title":"Phase II study of the novel epothilone BMS-247550 in patients with recurrent or metastatic non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy","volume":"21","author":"Delbaldo","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2008.01.016_bib25","article-title":"Phase II study of the novel epothilone BMS-247550 in patients with metastatic gastric adenocarcinoma previously treated with a taxane","volume":"21","author":"Ajani","year":"2002","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804908000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T19:15:10Z","timestamp":1557342910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804908000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0959804908000592"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2008.01.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}